



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/694,309 (Conf #3568)
Filing Date	27 October 2003
First Named Inventor	Peggy E. HELLBERG
Art Unit	
Examiner Name	
Attorney Docket Number	2395 US

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			
	A12	US-			
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-			
	A17	US-			
	A18	US-			
	A19	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A20	WO 00/08048 A2 & A3	02/17/2000	Fujisawa Pharm.		
	A21					
	A22					
	A23					
	A24					
	A25					

Examiner
Signature*Robert F. ...*Date
Considered

9/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/694,309 (Conf #35568)
Filing Date	27 October 2003
First Named Inventor	Peggy E. HELLBERG
Art Unit	1614
Examiner Name	
Attorney Docket Number	2395 US

U. S. PATENT DOCUMENTS

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
Z.F.	A1	US-	4,690,931	09/01/1987	Wick et al.	
Z.F.	A2	US-	5,151,444	09/29/1992	Ueno et al.	
Z.F.	A3	US-	B1 5,151,444	09/29/1992	Ueno et al.	
Z.F.	A4	US-	5,296,504	03/22/1994	Stjerschantz et al.	
Z.F.	A5	US-	5,352,708	10/04/1994	Woodward et al.	
Z.F.	A6	US-	5,422,368	06/06/1995	Stjerschantz et al.	
Z.F.	A7	US-	5,688,819	11/18/1997	Woodward et al.	
Z.F.	A8	US-	5,889,052	03/30/1999	Klimko et al.	
	A9	US-				
	A10	US-				
	A11	US-				
	A12	US-				
	A13	US-				
	A14	US-				
	A15	US-				
	A16	US-				
	A17	US-				
	A18	US-				
	A19	US-				

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)					
Z.F.	A20	WO 94/13275 A1		06/23/1994	Massachusetts Eye & Ear		
	A21						
	A22						
	A23						
	A24						
	A25						

Examiner
SignatureDate
Considered

9/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/694,309 (Conf #3568)		
		Filing Date	27 October 2003		
		First Named Inventor	Peggy E. HELLBERG		
		Art Unit	1614		
		Examiner Name			
Sheet	2	of	5	Attorney Docket Number	2395 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2.f	B1	Abler et al., "Photic injury triggers apoptosis of photoreceptor cells," IOVS 35(4):1517, 1996	
2.f	B2	Abler et al., "Photic injury triggers apoptosis of photoreceptor cells," Res Commun Mol Pathol Pharmacol, Vol. 92(2):177-189, 1996	
2.f	B3	Berson, "Retinitis Pigmentosa," Invest Ophthalmol Vis Sci, Vol. 34:1659-1676, 1993	
2.f	B4	Bressler et al., "Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration," Retina, Vol. 14:130-142, 1994	
2.f	B5	Bressler et al., "Age-related macular degeneration," Survey of Ophthalmology, Vol. 32(6):375-413, 1988	
2.f	B6	Collier et al., "Inhibition of photo-oxidative induced retinal damage by diphenylalkylamines," Invest Ophthal Vis Sci, Vol. 36:S516, 1995	
2.f	B7	Collier et al., "Prevention of photic induced retinal injury by eliprofil," Invest Ophthal Vis Sci, Vol. 40:S159, 1999	
2.f	B8	Cruickshank, et al., "Sunlight and Age-Related Macular Degeneration," Arch Ophthal, Vol. 111:514-518, 1993	
2.f	B9	Curcio et al., "Photoreceptor Loss in Age-Related Macular Degeneration," Invest Ophthal Vis Sci, Vol. 37(7):1236-1249, 1996	
2.f	B10	Edward et al., "Amelioration of Light-Induced Retinal Degeneration by a Calcium Overload Blocker," Arch Ophthal, Vol. 109:554-562, 1991	

Examiner Signature	<i>Zachary Fay</i>	Date Considered	9/26/04
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	3	of	5	Application Number	10/694,309 (Conf #3568)
				Filing Date	27 October 2003
				First Named Inventor	Peggy E. HELLBERG
				Art Unit	1614
				Examiner Name	
				Attorney Docket Number	2395 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Z.F	C1	Fakforovich et al., "Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor," Nature, Vol. 347:83-86, 1990	
Z.F	C2	Frasson et al., "Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse," Nat. Med. Vol. 5:1183-1187, 1990	
Z.F	C3	Fu et al., "Dexamethasone ameliorates retinal photic injury in albino rats," Exp Eye Res, Vol. 54:583-594, 1992	
Z.F	C4	Ge-Zhi et al., "Apoptosis in Human Retinal Degenerations," Trans AM Ophthal Soc, Vol. 4:411-430, 1996	
Z.F	C5	Green et al., "Pathologic features of senile macular degeneration," Ophthalmol, Vol. 92:615-627, 1985	
Z.F	C6	Green and Key, "Senile macular degeneration: a histopathologic study," Trans Am Ophthalmol Soc., Vol. 75:180-254, 1977	
Z.F	C7	Green and Enger, "Age-related macular degeneration histopathologic studies," Ophthalmol, Vol. 100:1519-1535, 1993	
Z.F	C8	Green and Kuchle, "Histopathologic studies of choroidal neovascularization," Indocyanine Green Angiography, Yannuzzi, L.A., Flower, R.W., Slakter, J.S. (Eds.), St. Louis: Mosby, Chapter 11:151-156, 1997	
Z.F	C9	Heckenlively, "RP Cone-rod degeneration," Trans Am Ophthalmol Soc., Vol. 85:438-470, 1987	
Z.F	C10	Johnstone, Nature Reviews, Drug Discovery, Vol. 1, Apr 2002	

Examiner Signature	<i>Zachary Foy</i>	Date Considered	9/26/01
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/694,309 (Conf #3568)
		Filing Date	27 October 2003
		First Named Inventor	Peggy E. HELLBERG
		Art Unit	1614
		Examiner Name	
Sheet 4 of 5	Attorney Docket Number	2395 US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2.f	D1	Kozaki et al., "Light-induced retinal damage in pigmented rabbit-2. Effect of alpha-tocopherol," Nippon Ganka Gakkai Zasshi, Vol. 98(10):948-954, 1994	
2.f	D2	Lam et al., "Amelioration of Retinal Photoc Injury in Albino Rats by Dimethylthiourea," Arch Ophthal, Vol. 108:1751-1757, 1990	
2.f	D3	Lam et al., "Methylprednisolone therapy in laser injury of the retina," Graefes Arch Clin Exp Ophthal, Vol. 231:729-736, 1993	
2.f	D4	LaVail et al., Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light," Proc Nat Acad Sci, Vol. 89:11249-11253, 1992	
2.f	D5	Li et al., "Desferrioxamine ameliorates retinal photic injury in albino rats," Eye Res, Vol. 10(2):133-144, 1991	
2.f	D6	Li et al., "Amelioration of retinal photic injury by a combination of flunarizine and dimethylthiourea," Exp Eye Res, Vol. 56:71-78, 1993	
2.f	D7	Naash et al., "Induced Acceleration of Photoreceptor Degeneration Transgenic Mice Expressing Mutant Rhodopsin," Invest Ophthal Vis Sci, Vol. 37(5):775-782, 1996	
2.f	D8	Nickells and Zack, "Apoptosis in ocular disease: a molecular overview," Ophthalmic Genet, Vol. 17:145-165, 1996	
2.f	D9	Noell et al., "Retinal damage by light in rats," Invest Ophthal Vis Sci, Vol. 5(5):450-472, 1966	
2.f	D10	Organisciak et al., "Amelioration of photic injury in rat retina by ascorbic acid: a histopathologic study," Invest Ophthal Vis Sci, Vol. 26:1589-1598, 1985	

Examiner Signature	<i>Robert Foy</i>	Date Considered	9/26/04
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/694,309 (Conf #3568)
Filing Date	27 October 2003
First Named Inventor	Peggy E. HELLBERG
Art Unit	1614
Examiner Name	
Attorney Docket Number	2395 US

Sheet

5

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2f	E1	Organisciak et al., "Protection by Dimethylthiourea Against Retinal Light Damage in Rats," Invest Ophthal Vis Sci, Vol. 33(5):1599-1609, 1992	
2f	E2	Pagon, "Retinitis Pigmentosa," Survey Ophthalmol, Vol. 33:137-177, 1988	
2f	E3	Pruett, "Retinitis pigmentosa: clinical observations and correlations," Trans Am Ophthalmol Soc., Vol. 81:693-735, 1983	
2f	E4	Rapp et al., "Evaluation of retinal susceptibility to light damage in pigmented rats supplemented with beta-carotene," Cur Eye Res, Vol. 15:219-223, 1995	
2f	E5	Schneider et al., "Photocoagulation of well-defined choroidal neovascularization in age-related macular degeneration," Retina, Vol. 18:242-250, 1998	
2f	E6	Taylor et al., "Long-term Effects of Visible Light on the Eye," Arch Ophthalmol, Vol. 110:99-104, 1992	
2f	E7	Young, "Solar radiation and age-related macular degeneration," Survey Ophthal, Vol. 32:252-269, 1988	
	E8		
	E9		
	E10		

Examiner Signature	<i>Robert Fay</i>	Date Considered	9/26/04
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.